Multidisciplinary Studies of HIV and Viral Hepatitis Co-Infection (R01, R21)

Funding Agency:
National Institutes of Health

The purpose of this Funding Opportunity Announcement (FOA) is to fill gaps in our understanding of a) the pathogenic interactions between HIV and hepatitis viruses, b) co-morbidities associated with HIV/hepatitis virus co-infection, and c) the effectiveness of interferon-free direct-acting antiviral drug regimens to treat HIV/HCV co-infection. This FOA is informed by priority areas in the 2011 HHS Action Plan, Combating the Silent Epidemic of Viral Hepatitis: Action Plan for the Prevention, Care and Treatment of Viral Hepatitis

Although this funding opportunity uses the R01 grant mechanism, it runs in parallel with a program announcement of identical scientific scope,  PAR-14-254, which uses the exploratory/developmental (R21) grant mechanism.

Deadlines: Jan. 7, May 7, Sep. 7

PAR-14-255 Expiration Date May 8, 2017




Medical - Basic Science
Medical - Clinical Science

External Deadline

May 7, 2017